Anna Duckworth1, Michael A Gibbons2, Richard J Allen3, Howard Almond4, Robin N Beaumont5, Andrew R Wood5, Katie Lunnon5, Mark A Lindsay6, Louise V Wain7, Jess Tyrrell5, Chris J Scotton8. 1. Institute of Biomedical & Clinical Science, College of Medicine & Health, University of Exeter, Exeter, UK; Exeter Patients in Collaboration for PF, Exeter, UK. 2. Institute of Biomedical & Clinical Science, College of Medicine & Health, University of Exeter, Exeter, UK; Exeter Patients in Collaboration for PF, Exeter, UK; Respiratory Medicine Department, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK. 3. Department of Health Sciences, University of Leicester, Leicester, UK. 4. Exeter Patients in Collaboration for PF, Exeter, UK. 5. Institute of Biomedical & Clinical Science, College of Medicine & Health, University of Exeter, Exeter, UK. 6. Department of Pharmacy and Pharmacology, University of Bath, Bath, UK. 7. Department of Health Sciences, University of Leicester, Leicester, UK; National Institute for Health Research, Leicester Respiratory Biomedical Research Centre, Glenfield Hospital, Leicester, UK. 8. Institute of Biomedical & Clinical Science, College of Medicine & Health, University of Exeter, Exeter, UK; Exeter Patients in Collaboration for PF, Exeter, UK. Electronic address: c.j.scotton@exeter.ac.uk.
Abstract
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a fatal lung disease accounting for 1% of UK deaths. In the familial form of pulmonary fibrosis, causal genes have been identified in about 30% of cases, and a majority of these causal genes are associated with telomere maintenance. Prematurely shortened leukocyte telomere length is associated with IPF and chronic obstructive pulmonary disease (COPD), a disease with similar demographics and shared risk factors. Using mendelian randomisation, we investigated evidence supporting a causal role for short telomeres in IPF and COPD. METHODS: Mendelian randomisation inference of telomere length causality was done for IPF (up to 1369 cases) and COPD (13 538 cases) against 435 866 controls of European ancestry in UK Biobank. Polygenic risk scores were calculated and two-sample mendelian randomisation analyses were done using seven genetic variants previously associated with telomere length, with replication analysis in an IPF cohort (2668 cases vs 8591 controls) and COPD cohort (15 256 cases vs 47 936 controls). FINDINGS: In the UK Biobank, a genetically instrumented one-SD shorter telomere length was associated with higher odds of IPF (odds ratio [OR] 4·19, 95% CI 2·33-7·55; p=0·0031) but not COPD (1·07, 0·88-1·30; p=0·51). Similarly, an association was found in the IPF replication cohort (12·3, 5·05-30·1; p=0·0015) and not in the COPD replication cohort (1·04, 0·71-1·53; p=0·83). Meta-analysis of the two-sample mendelian randomisation results provided evidence inferring that shorter telomeres cause IPF (5·81 higher odds of IPF, 95% CI 3·56-9·50; p=2·19 × 10-12). There was no evidence to infer that telomere length caused COPD (OR 1·07, 95% CI 0·90-1·27; p=0·46). INTERPRETATION: Cellular senescence is hypothesised as a major driving force in IPF and COPD; telomere shortening might be a contributory factor in IPF, suggesting divergent mechanisms in COPD. Defining a key role for telomere shortening enables greater focus in telomere-related diagnostics, treatments, and the search for a cure in IPF. Investigation of therapies that improve telomere length is warranted. FUNDING: Medical Research Council.
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a fatal lung disease accounting for 1% of UK deaths. In the familial form of pulmonary fibrosis, causal genes have been identified in about 30% of cases, and a majority of these causal genes are associated with telomere maintenance. Prematurely shortened leukocyte telomere length is associated with IPF and chronic obstructive pulmonary disease (COPD), a disease with similar demographics and shared risk factors. Using mendelian randomisation, we investigated evidence supporting a causal role for short telomeres in IPF and COPD. METHODS: Mendelian randomisation inference of telomere length causality was done for IPF (up to 1369 cases) and COPD (13 538 cases) against 435 866 controls of European ancestry in UK Biobank. Polygenic risk scores were calculated and two-sample mendelian randomisation analyses were done using seven genetic variants previously associated with telomere length, with replication analysis in an IPF cohort (2668 cases vs 8591 controls) and COPD cohort (15 256 cases vs 47 936 controls). FINDINGS: In the UK Biobank, a genetically instrumented one-SD shorter telomere length was associated with higher odds of IPF (odds ratio [OR] 4·19, 95% CI 2·33-7·55; p=0·0031) but not COPD (1·07, 0·88-1·30; p=0·51). Similarly, an association was found in the IPF replication cohort (12·3, 5·05-30·1; p=0·0015) and not in the COPD replication cohort (1·04, 0·71-1·53; p=0·83). Meta-analysis of the two-sample mendelian randomisation results provided evidence inferring that shorter telomeres cause IPF (5·81 higher odds of IPF, 95% CI 3·56-9·50; p=2·19 × 10-12). There was no evidence to infer that telomere length caused COPD (OR 1·07, 95% CI 0·90-1·27; p=0·46). INTERPRETATION: Cellular senescence is hypothesised as a major driving force in IPF and COPD; telomere shortening might be a contributory factor in IPF, suggesting divergent mechanisms in COPD. Defining a key role for telomere shortening enables greater focus in telomere-related diagnostics, treatments, and the search for a cure in IPF. Investigation of therapies that improve telomere length is warranted. FUNDING: Medical Research Council.
Authors: Richard J Allen; Amy Stockwell; Justin M Oldham; Beatriz Guillen-Guio; David A Schwartz; Toby M Maher; Carlos Flores; Imre Noth; Brian L Yaspan; R Gisli Jenkins; Louise V Wain Journal: Thorax Date: 2022-06-10 Impact factor: 9.102
Authors: Dragana M Jovanovic; Martina Šterclová; Nesrin Mogulkoc; Katarzyna Lewandowska; Veronika Müller; Marta Hájková; Michael Studnicka; Jasna Tekavec-Trkanjec; Simona Littnerová; Martina Vašáková Journal: Respir Res Date: 2022-05-27
Authors: Han Yuan; Ilya Soifer; Michelle Chan; Tobias M Maile; Rebecca Y Wang; Andrea Ireland; Jonathon J O'Brien; Jérôme Goudeau; Leanne J G Chan; Twaritha Vijay; Adam Freund; Cynthia Kenyon; Bryson D Bennett; Fiona E McAllister; David R Kelley; Margaret Roy; Robert L Cohen; Arthur D Levinson; David Botstein; David G Hendrickson Journal: Elife Date: 2022-02-04 Impact factor: 8.713
Authors: John A Mackintosh; Stephanie T Yerkovich; Maxine E Tan; Luke Samson; Peter Ma Hopkins; Daniel C Chambers Journal: Front Immunol Date: 2021-04-16 Impact factor: 7.561
Authors: Piotr Macek; Mieszko Wieckiewicz; Rafal Poreba; Pawel Gac; Katarzyna Bogunia-Kubik; Marta Dratwa; Anna Wojakowska; Grzegorz Mazur; Helena Martynowicz Journal: J Clin Med Date: 2022-01-20 Impact factor: 4.241